Welcome to the ADRIC Research Programme
ADRIC - Adverse Drug Reactions in Children
ADRIC is a vital research programme awarded 5 years funding by the National
Institute of Health Research (NIHR) working in collaboration
In all, five studies were carried out, some of which took place simultaneously:
The investigation of adverse drug reactions among acute
admissions of children to
ADRIC 2: The year long Investigation of adverse drug reactions that occur amongst in-patients commenced in October 2009 and is now complete. The analysis has been carried out and publications of the study are now pending.
ADRIC 3: The systematic review combined evidence from the studies which have investigated adverse drug reactions in children and described methods used for identifying these ADRs. The systematic review paper has been published in PLoS ONE (Click here to go to the publication)
ADRIC-QUAL: This study explored families' and clinicians' experiences of paediatric adverse drug reactions with a view to improve communication between families and clinicians when a suspected ADR has occurred. The findings of parents' ADR experiences have been published in PLoS ONE (Click here to go to the publication) and the results of parents participation in the yellow card scheme has been published in the British Journal of Clinical Pharmacology (Click here to go to the publication). Further publications of additional study findings are pending.
ADRIC 5: This study uses the findings from the first four studies to produce tools that will help to both identify and communicate ADRs. The Liverpool Causality Assessment Tool (LCAT) was developed and the paper was published in PLoS ONE (Click here to go to the publication). Child and parent information leaflets are currently being developed. The LCAT e-learning package is under development before being validated.
The impact of this programme will be invaluable as awareness of adverse drug reactions will be raised, leading to the production of national guidelines for prevention. This understanding will ultimately result in much improved safety in prescribing medicines for children and young people.
The ADRIC team would like to take this opportunity to thank everyone who has supported them so far throughout all the studies and look forward to your continued co-operation. If you would like any further information regarding the ADRIC programme please contact Barbara Richards, former ADRIC Administrator at Barbara.email@example.com.